barrett's oesophagus Flashcards
definition of Barrett’s
metaplasia of the normal stratified squamous epithelium of the distal oesophagus to columnar epithelium
result of chronic GORD
aetiology of barrett’s
chronic GORD
combined acid and bile reflux are the primary causative agents.
RF for barrett’s
>50
obesity
male
white
FH or Barrett’s or oesophageal carcinoma
epidemiology of Barrett’s
pts with history of symptomatic GORD rates approx 8%
screening in asymptomatic = approx 6%
sx of barrett’s
GORD - retrosternal burning, antacids make it better, spicy food worse, alcohol worse (relaxes the LOS), acid brash
heart burn
risk factors
dysphagia - uncommon
chest pain
cough
dysponea
history of aspiration pneumonia
signs of barrett’s
wheezing
laryngitis
Ix for barrett’s
biopsy of endoscopically visible columnarisation allows histological corroboration
length should be recorded using Prague classification
Mx of Barrett’s
focus on preventing oesophageal adenocarcinoma
risk of progression is low
RF for progression:
- increased age
- male
- long segment of oesophagus involved
- dysplasia
pts w/o dysplasia, length of involved oesophagus <3cm = discharged from surveillance programs, endoscopic assessment every 3yrs if appropriate
if high grade dysplasia/intramural carcinoma detected = endoscopic resection or mucosal radiofrequency ablation
low grade dysplasia - should be confirmed by repeat examination after 6mo prior to radiofrequency ablation
complications of barrett’s
dysplasia and adenocarcinoma
oesophageal stricture
QOL deficit
Px of barrett’s
adenocarcinomas discovered while screening for Barrett’s oesophagus are early-stage lesions and have good prognosis (5-year survival >85%).
Even with aggressive acid suppression, proton-pump inhibitor treatment does not lead to regression of Barrett’s oesophagus and the rate of progression to adenocarcinoma is approximately 0.25% to 0.4% per year
There are reports that anti-reflux surgery alone can lead to regression of Barrett’s oesophagus in more than 25% of patients, and that surgery lowers the risk for progression to adenocarcinoma.[86][87] Evidence is mixed, however.